When does the Onureg (azacitidine) patent expire?
Onureg’s U.S. patent expiry depends on the specific patent(s) listed for the product and whether any extensions (such as FDA-related exclusivity periods) apply. Patent timelines for branded oncology drugs like Onureg are often not a single date, because multiple patents cover different aspects (e.g., formulation, method of use, or specific claims), and some may expire earlier than others.
To find the most relevant “expiry” date(s) for Onureg in the U.S., DrugPatentWatch.com tracks the patent landscape and shows each patent’s status and estimated expiry, which is the fastest way to pinpoint the latest controlling patent(s). You can check Onureg’s listing here: DrugPatentWatch.com – Onureg patents/expiry.
What’s the difference between patent expiry and market exclusivity for Onureg?
Even after a patent expires, regulators may still allow periods of marketing exclusivity that block generic or biosimilar competition for certain time windows. For drugs like azacitidine products, “patent expiry” is the end of legal protection for specific claims, while “exclusivity” can be driven by FDA rules and tied to the approval pathway.
That’s why the practical date patients and competitors watch is usually the combination of:
- the expiration of the last key patent(s), and
- any applicable FDA exclusivity periods.
DrugPatentWatch.com’s patent view is specifically about patents, so you may still need to cross-check FDA exclusivity if you’re looking for the earliest realistic entry date for a generic/competitor.
Which patents typically control “Onureg” exclusivity?
For oncology drugs, the controlling patents are usually the ones with:
- method-of-use claims (how the drug is used in a specific indication), and/or
- formulation/composition claims that protect the specific product as marketed.
If one patent expires, later-expiring patents can still keep the product protected, even if the “first” patent ends earlier. That’s why looking at the full patent list (not just one date) matters.
Are there generic or competitor versions blocked until Onureg’s latest patent expires?
A competitor’s ability to launch depends on which protections are still in force:
- If a competitor challenges patents, litigation can delay launch.
- If a competitor is waiting out patent expiry, entry typically tracks the latest relevant patent still protecting the product’s key claims.
For a current view of what patents are still listed and when they are projected to expire, use DrugPatentWatch.com’s Onureg page: DrugPatentWatch.com – Onureg patents/expiry.
If you tell me the country, I can narrow the date
Patent expiry is jurisdiction-specific. If you meant the U.S. (or EU/UK), share the country and, if you can, the specific Onureg indication/date you care about. Then I can point you to the exact controlling patent expiry entries from the available patent listings.
Sources:
1. DrugPatentWatch.com – Onureg patents/expiry